{"protocolSection":{"identificationModule":{"nctId":"NCT05879744","orgStudyIdInfo":{"id":"CLN-978-001"},"organization":{"fullName":"Cullinan Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)","officialTitle":"A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-05-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-04","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-05","studyFirstSubmitQcDate":"2023-05-18","studyFirstPostDateStruct":{"date":"2023-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-04-30","lastUpdatePostDateStruct":{"date":"2024-05-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Cullinan Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)."},"conditionsModule":{"conditions":["NHL","NHL, Relapsed, Adult"],"keywords":["Relapsed/Refractory B-cell Non-Hodgkin Lymphoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A Dose Escalation","type":"EXPERIMENTAL","description":"Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts","interventionNames":["Drug: CLN-978"]},{"label":"Part B Dose Expansion","type":"EXPERIMENTAL","description":"Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.","interventionNames":["Drug: CLN-978"]}],"interventions":[{"type":"DRUG","name":"CLN-978","description":"CD19xCD3 T cell engager","armGroupLabels":["Part A Dose Escalation","Part B Dose Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs","description":"Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays","timeFrame":"24 months"},{"measure":"Define dose regimen for CLN-978","description":"Dose-limiting Toxicities (DLTs)","timeFrame":"24 months"}],"secondaryOutcomes":[{"measure":"Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL","description":"Overall response rate (ORR)","timeFrame":"24 months"},{"measure":"Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL","description":"Complete response (CR)","timeFrame":"24 months"},{"measure":"Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL","description":"Duration of response (DOR)","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: AUC","description":"Area under-the-concentration-time curve of CLN-978","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: Cmax","description":"Maximum concentration of CLN-978","timeFrame":"24 months"},{"measure":"Select PK parameters of CLN-978: Half-life","description":"Half-life of CLN-978","timeFrame":"24 months"},{"measure":"Immunogenicity of CLN-978 and potential impact on drug exposure","description":"Incidence of anti-drug antibodies to CLN-978","timeFrame":"24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) PS ≤ 2\n* Documented diagnosis of one of the below CD19+ B-cell neoplasms according to WHO classification (Swerdlow et al., 2016) or WHO classification 2008:\n\n  1. Diffuse large B-cell lymphoma - de novo or transformed\n  2. High-grade B-cell lymphoma\n  3. Primary mediastinal large B-cell lymphoma\n  4. Follicular lymphoma\n  5. Mantle cell lymphoma\n  6. Marginal zone lymphoma (nodal, extranodal, or mucosa-associated)\n* Relapsed, progressive, and/or refractory disease after at least 2 lines of therapy.\n* For Part B expansion cohorts:\n\n  1. Cohort B1: R/R DLBCL that has relapsed after at least 2 prior therapies including a CD20 monoclonal antibody and anthracycline.\n  2. Cohort B2: R/R FL (grade 1-3a) that has relapsed after at least 2 prior therapies including CD20 monoclonal antibody and an alkylating agent.\n  3. Cohort B3: Other R/R B-NHL.\n* Measurable disease defined as ≥1 measurable nodal lesion (long axis \\>1.5 cm and short axis \\>1.0 cm) or ≥1 measurable extra-nodal lesion (long axis \\>1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI) AND baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion(s) compatible with CT- or MRI-defined anatomical tumor sites.\n* Laboratory parameters including the following:\n\n  1. Lymphocyte count \\< 5 x 10\\^9/L\n  2. Platelet count ≥ 75 x 10\\^9/L\n  3. Absolute neutrophil count ≥ 1.0 x 10\\^9/L; growth factor support allowed in cases of documented bone marrow involvement\n  4. Hemoglobin ≥ 9 g/dL, with or without transfusion\n  5. Creatinine clearance ≥ 45 mL/min\n  6. Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except patients with confirmed Gilbert's Syndrome\n  7. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless attributed to hepatic involvement by lymphoma)\n\nExclusion Criteria:\n\n* Primary CNS lymphoma or known CNS involvement by lymphoma at study screening\n* Known past or current malignancy other than the inclusion diagnosis\n* Known clinically significant cardiac disease\n* Significant central nervous system disease\n* Prior organ allograft\n* Confirmed history or current autoimmune disorder or other disease requiring ongoing immune suppression\n* Active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or known Human Immunodeficiency Virus (HIV) infection\n* Live virus vaccines within 28 days of the first dose of CLN-978, during treatment, and until the end of last dose of CLN-978\n* Known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including coronavirus disease of 2019 (COVID-19) infection, at the time of enrollment or within 7 days of the first dose of CLN-978.\n* Prior treatment with any of the following:\n\n  1. Allogeneic HSCT\n  2. Autologous HSCT within 30 days prior to the first dose of CLN-978\n  3. Chimeric antigen receptor T cell therapy (CAR-T) within 30 days prior to the first dose of CLN-978\n  4. Any investigational CD19 x CD3 T cell engager (TCE)\n  5. Unconjugated CD19 monoclonal antibody ≤ 4 weeks prior to the first dose CLN-978\n  6. Radio-conjugated or CD19 antibody-drug conjugate ≤ 12 weeks prior to the first dose CLN-978\n  7. Investigational or standard of care monoclonal antibodies, chemotherapy, or other investigational agent ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of CLN-978\n  8. Radiation therapy (XRT), with the exception of focal treatment for symptom control, ≤ 4 weeks of the first dose of CLN-978\n* Woman of child-bearing potential who is pregnant, breast-feeding, or plans to become pregnant\n* Male patients who plan to father a child or donate sperm within 120 days of last study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"University of Alabama at Birmingham","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"City of Hope","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Winship Cancer Institute at Emory University","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Hackensack University Medical Center","city":"Hackensack","state":"New Jersey","zip":"07601","country":"United States","geoPoint":{"lat":40.88593,"lon":-74.04347}},{"facility":"University of Texas Southwestern Medical Center","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D012008","term":"Recurrence"},{"id":"D016393","term":"Lymphoma, B-Cell"}],"ancestors":[{"id":"D008223","term":"Lymphoma"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}